Tyroserleutide

Tyroserleutide (YSL), isolated from the degradation products of porcine spleen^[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo^[2]. IC50 & Target: Antitumor tripeptide^[1][2] In Vitro: Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells^[1].
Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression^[2].
Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells^[2].
Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration^[2].
In Vivo: Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice^[1].